⚕ GalenOps field
←

SITE012-0266

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-01-03

AEs
10
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-02-09 (study day 19); relationship: N

mild assessed

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 114); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 159); relationship: Y

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-22 (study day 182); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 204); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-18 (study day 270); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-12 (study day 325); relationship: not assessed

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-15 (study day 328); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-03 (study day 378); relationship: not assessed

severe assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-07-13 (study day 539); relationship: N

Data queries

No data queries.